Rivaroxaban fails to decrease VTE incidence during trial period - Healio

Rivaroxaban fails to decrease VTE incidence during trial period  Healio

Treatment with rivaroxaban did not significantly decrease incidence of venous thromboembolism or death from VTE in a 180-day trial period, according to results ...